Andres Paler-Martinez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andres Paler-Martinez has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Jason A. Hackney
Computational Sciences, gRED, Genentech, South San Francisco, USA
3 shared publications A. Francesca Setiadi
Research, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
2 shared publications- Cary D. Austin
Department of Pathology, Genentech, A Member of the Roche Group
2 shared publications - Eric Suto
Department of Translational Immunology, Genentech, South San Francisco, USA
2 shared publications - Eugene Varfolomeev
Research, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
2 shared publications - Kate Senger
Molecular Biology, Genentech, South San Francisco, CA 2
2 shared publications
Latest Publications
- Open Access
- 14 January 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (1) , e0244439
The peptide symporter SLC15a4 is essential for the development of systemic lupus erythematosus in murine models
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease representing a serious unmet medical need. The disease is associated with the loss of self-tolerance and exaggerated B cell activation, resulting in autoantibody production and the formation of immune complexes that accumulate in the kidney, causing glomerulonephritis. TLR7, an important mediator of the innate immune response, drives the expression of type-1 interferon (IFN), which leads to expression of type-1 IFN induced genes and aggravates lupus pathology. Because the lysosomal peptide symporter slc15a4 is critically required for type-1 interferon production by pDC, and for certain B cell functions in response to TLR7 and TLR9 signals, we considered it as a potential target for pharmacological intervention in SLE. We deleted the slc15a4 gene in C57BL/6, NZB, and NZW mice and found that pristane-challenged slc15a4-/- mice in the C57BL/6 background and lupus prone slc15a4-/- NZB/W F1 mice were both completely protected from lupus like disease. In the NZB/W F1 model, protection persisted even when disease development was accelerated with an adenovirus encoding IFNα, emphasizing a broad role of slc15a4 in disease initiation. Our results establish a non-redundant function of slc15a4 in regulating both innate and adaptive components of the immune response in SLE pathobiology and suggest that it may be an attractive drug target.
- 14 January 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (1) , e0244439
Open AccessThe peptide symporter SLC15a4 is essential for the development of systemic lupus erythematosus in murine models
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease representing a serious unmet medical need. The disease is associated with the loss of self-tolerance and exaggerated B cell activation, resulting in autoantibody production and the formation of immune complexes that accumulate in the kidney, causing glomerulonephritis. TLR7, an important mediator of the innate immune response, drives the expression of type-1 interferon (IFN), which leads to expression of type-1 IFN induced genes and aggravates lupus pathology. Because the lysosomal peptide symporter slc15a4 is critically required for type-1 interferon production by pDC, and for certain B cell functions in response to TLR7 and TLR9 signals, we considered it as a potential target for pharmacological intervention in SLE. We deleted the slc15a4 gene in C57BL/6, NZB, and NZW mice and found that pristane-challenged slc15a4-/- mice in the C57BL/6 background and lupus prone slc15a4-/- NZB/W F1 mice were both completely protected from lupus like disease. In the NZB/W F1 model, protection persisted even when disease development was accelerated with an adenovirus encoding IFNα, emphasizing a broad role of slc15a4 in disease initiation. Our results establish a non-redundant function of slc15a4 in regulating both innate and adaptive components of the immune response in SLE pathobiology and suggest that it may be an attractive drug target.
- Open Access
- 2 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 13 (634)
The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells
Inhibiting the kinase IRAK4 may suppress a multicellular autoinflammatory loop in patients with lupus.
- 2 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 13 (634)
Open AccessThe kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells
Inhibiting the kinase IRAK4 may suppress a multicellular autoinflammatory loop in patients with lupus.
- 18 April 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 10 (475)
The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation
A small-molecule inhibitor of the kinase TPL2 shows efficacy in rodent models of inflammation.
- 18 April 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 10 (475)
The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation
A small-molecule inhibitor of the kinase TPL2 shows efficacy in rodent models of inflammation.